A detailed history of Pro Share Advisors LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 50,234 shares of ERAS stock, worth $146,683. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,234
Previous 26,849 87.1%
Holding current value
$146,683
Previous $63,000 117.46%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.17 - $3.28 $50,745 - $76,702
23,385 Added 87.1%
50,234 $137,000
Q2 2024

Aug 13, 2024

BUY
$1.79 - $2.63 $3,153 - $4,634
1,762 Added 7.02%
26,849 $63,000
Q1 2024

May 08, 2024

BUY
$1.67 - $2.55 $3,470 - $5,298
2,078 Added 9.03%
25,087 $51,000
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $4,430 - $6,605
2,653 Added 13.03%
23,009 $49,000
Q3 2023

Nov 13, 2023

BUY
$1.97 - $2.91 $210 - $311
107 Added 0.53%
20,356 $40,000
Q2 2023

Aug 10, 2023

BUY
$2.57 - $3.3 $5,636 - $7,236
2,193 Added 12.15%
20,249 $55,000
Q1 2023

May 11, 2023

SELL
$2.74 - $4.44 $1,123 - $1,820
-410 Reduced 2.22%
18,056 $54,000
Q4 2022

Feb 02, 2023

BUY
$3.89 - $8.57 $4,049 - $8,921
1,041 Added 5.97%
18,466 $79,000
Q3 2022

Nov 04, 2022

BUY
$5.82 - $10.68 $3,783 - $6,942
650 Added 3.87%
17,425 $135,000
Q2 2022

Aug 01, 2022

SELL
$4.58 - $8.72 $35,531 - $67,649
-7,758 Reduced 31.62%
16,775 $93,000
Q1 2022

May 10, 2022

BUY
$8.6 - $15.48 $24,578 - $44,241
2,858 Added 13.19%
24,533 $211,000
Q4 2021

Feb 08, 2022

BUY
$12.51 - $22.75 $271,154 - $493,106
21,675 New
21,675 $338,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $357M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.